| Observed frequency and challenges of variant reclassification in a hereditary cancer clinic S Macklin, N Durand, P Atwal, S Hines Genetics in Medicine 20 (3), 346-350, 2018 | 106 | 2018 |
| Targeting reactive oxygen species in development and progression of pancreatic cancer N Durand, P Storz Expert review of anticancer therapy 17 (1), 19-31, 2017 | 75 | 2017 |
| Src family kinases differentially influence glioma growth and motility LJ Lewis-Tuffin, R Feathers, P Hari, N Durand, Z Li, FJ Rodriguez, ... Molecular oncology 9 (9), 1783-1798, 2015 | 63 | 2015 |
| Modifiers of mesenchymal stem cell quantity and quality AL Russell, R Lefavor, N Durand, L Glover, AC Zubair Transfusion 58 (6), 1434-1440, 2018 | 60 | 2018 |
| Protein kinase D enzymes as regulators of EMT and cancer cell invasion N Durand, S Borges, P Storz Journal of clinical medicine 5 (2), 20, 2016 | 53 | 2016 |
| Insights into the use of mesenchymal stem cells in COVID-19 mediated acute respiratory failure N Durand, J Mallea, AC Zubair NPJ Regenerative medicine 5 (1), 17, 2020 | 51 | 2020 |
| Functional and therapeutic significance of protein kinase D enzymes in invasive breast cancer N Durand, S Borges, P Storz Cellular and Molecular Life Sciences 72, 4369-4382, 2015 | 36 | 2015 |
| Feasibility, potency, and safety of growing human mesenchymal stem cells in space for clinical application P Huang, AL Russell, R Lefavor, NC Durand, E James, L Harvey, ... npj Microgravity 6 (1), 16, 2020 | 35 | 2020 |
| Protein kinase D-mediated phosphorylation at Ser99 regulates localization of p21-activated kinase 4 LI Bastea, H Döppler, SE Pearce, N Durand, SJ Spratley, P Storz Biochemical Journal 455 (2), 251-260, 2013 | 29 | 2013 |
| Effect of comedications and endotoxins on mesenchymal stem cell secretomes, migratory and immunomodulatory capacity N Durand, A Russell, AC Zubair Journal of Clinical Medicine 8 (4), 497, 2019 | 21 | 2019 |
| Protein Kinase D1 regulates focal adhesion dynamics and cell adhesion through Phosphatidylinositol-4-phosphate 5-kinase type-l γ N Durand, LI Bastea, J Long, H Döppler, K Ling, P Storz Scientific reports 6 (1), 35963, 2016 | 17 | 2016 |
| Autologous versus allogeneic mesenchymal stem cell therapy: The pros and cons N Durand, AC Zubair Surgery 171 (5), 1440-1442, 2022 | 8 | 2022 |
| Src-mediated tyrosine phosphorylation of protein kinase D2 at focal adhesions regulates cell adhesion N Durand, LI Bastea, H Döppler, T Eiseler, P Storz Scientific reports 7 (1), 9524, 2017 | 8 | 2017 |
| Feasibility and safety of low-dose mesenchymal stem cell infusion in lung transplant recipients DB Erasmus, N Durand, FA Alvarez, T Narula, DO Hodge, AC Zubair Stem Cells Translational Medicine 11 (9), 891-899, 2022 | 7 | 2022 |
| The phosphorylation status of PIP5K1C at serine 448 can be predictive for invasive ductal carcinoma of the breast N Durand, S Borges, T Hall, L Bastea, H Döppler, BH Edenfield, ... Oncotarget 9 (91), 36358, 2018 | 5 | 2018 |
| Mesenchymal Stem Cell Therapy in Acute Intracerebral Hemorrhage: A Dose-Escalation Safety and Tolerability Trial NC Durand, HG Kim, VN Patel, MT Turnbull, JL Siegel, DO Hodge, ... Neurocritical care, 1-11, 2023 | 1 | 2023 |
| Phase 1, dose escalation, nonrandomized, open-label, clinical trial evaluating the safety and preliminary efficacy of allogenic adipose-derived mesenchymal stem cells for … A Ramos-Fresnedo, R Al-Kharboosh, EL Twohy, AN Basil, ... Neurosurgery practice 4 (4), e00062, 2023 | 1 | 2023 |
| Particulates are everywhere, but are they harmful in cell and gene therapies? SA Molina, SJ Davies, D Sethi, S Oh, N Durand, M Scott, LC Davies, ... Cytotherapy 24 (12), 1195-1200, 2022 | 1 | 2022 |
| CELLKINE CLINICAL TRIAL: FIRST REPORT FROM A PHASE I TRIAL OF ALLOGENEIC BONE MARROW-DERIVED MESENCHYMAL STEM CELLS IN SUBJECTS WITH PAINFUL LUMBAR FACET JOINT ARTHROPATHY D Yan, A Zubair, M Osborne, RP Rosado, JA Stone, V Lehman, N Durand, ... Cytotherapy 26 (6), e8-e9, 2024 | | 2024 |
| Bioprocessing considerations for generation of iPSCs intended for clinical application: Perspectives from the ISCT Emerging Regenerative Medicine Technology Working Group HW Song, JN Solomon, F Masri, A Mack, N Durand, E Cameau, N Dianat, ... Cytotherapy, 2024 | | 2024 |
